|
Abraxis receives European marketing approval for Abraxane(R) |
|
|
|
|
News -
Nanomedicine and Drug Delivery News Archive
|
|
Tuesday, 22 January 2008 |
|
Abraxis BioScience announced that the European Medicines Agency (EMEA) granted marketing approval for Abraxane(R) (paclitaxel protein-bound particles for injectable suspension) for the treatment of metastatic breast cancer in patients who have failed first-line treatment.
Abraxane(R) is a proprietary nanoparticle formulation that entraps paclitaxel into particles comprised of an albumin shell. This formulation has been developed using Abraxis' nab(TM) technology. This technology takes advantage of a specialized protein called SPARC (Secreted Protein Acidic and Rich in Cysteine) into the tumor's interstitium that acts as a highly charged receptor to specifically attract and bind albumin. The SPARC protein function is to concentrate albumin-bound nutrients within the tumor's interstitium to prevent nutrients from diffusing outside the tumor cell.
Abraxis expects to launch Abraxane(R) in European countries in mid-2008. Abraxane(R) is already approved in US and Canada.
Source: Abraxis BioScience, Inc. |
